One Turn · Cambridge, Massachusetts, US · October 23, 2026
Personalized mRNA vaccine cuts melanoma recurrence risk in trial
Trial results show intismeran, a personalized mRNA vaccine from Moderna and Merck custom-made for each patient's tumor, significantly reduced the risk of melanoma recurrence or death within two years after surgery. Six melanoma specialists told CNBC the results are clinically meaningful, despite a negative reaction from Wall Street.